Innovent Biologics (HKG:1801) recorded a total product revenue of over 2.4 billion yuan in the first quarter, up 40% from a year prior, a Thursday Hong Kong bourse filing said.

The drugmaker launched four new products in the quarter, comprising Dovbleron, Limertinib, and Jaypirca in the oncology niche, and SYCUME in the field of general biomedicine.

To date, the company has 15 approved products, three new drug applications under regulatory review, four assets in phase III or pivotal clinical trials, and 15 more molecules in early clinical stage.